Guide · Updated 2026
Ozempic vs. Wegovy
Same molecule, different label, different dose, different insurance story. Here's what actually matters when you're choosing between them.
At a glance
| Ozempic | Wegovy | |
|---|---|---|
| Active ingredient | Semaglutide | Semaglutide |
| FDA-approved use | Type 2 diabetes; CV risk reduction | Chronic weight management (BMI ≥30, or ≥27 with a comorbidity) |
| Max weekly dose | 2 mg | 2.4 mg |
| Titration schedule | 0.25 → 0.5 → 1 → 2 mg (4-week steps) | 0.25 → 0.5 → 1 → 1.7 → 2.4 mg (4-week steps) |
| Average weight loss | ~6% at the 1 mg dose (diabetes trials) | ~15% at 2.4 mg (STEP-1) |
| List price | ~$970/mo | ~$1,350/mo |
| Insurance coverage | Widely covered for diabetes | Some employer plans; rare on Medicare |
| Cardiovascular label | Reduces MACE in T2D + CV disease | SELECT trial: reduces MACE in obesity + CV disease (added 2024) |
What's actually different
The molecule is identical: both pens deliver semaglutide, a once-weekly GLP-1 receptor agonist that slows gastric emptying, blunts appetite signaling, and improves insulin sensitivity. What differs is the maximum dose Novo Nordisk studied and got FDA approval for. Wegovy's higher 2.4 mg dose drives stronger appetite suppression — and more weight loss — than Ozempic's 2 mg cap. Beyond dose, the pens look different, and Wegovy has an extra titration step (1.7 mg) so patients ramp up more gradually.
What the trials showed
Wegovy's flagship trial, STEP-1, followed 1,961 adults with obesity for 68 weeks. Average weight loss on 2.4 mg semaglutide plus lifestyle counseling was 14.9%, vs. 2.4% on placebo. About 32% of patients lost ≥20% of their starting weight. Ozempic's SUSTAIN trials, run in people with type 2 diabetes, showed A1c reductions of 1.5–1.8% and weight loss of 4–6% at the 1 mg dose over 30–56 weeks.
The SELECT trial (2023) later showed that Wegovy 2.4 mg reduced major cardiovascular events (heart attack, stroke, cardiovascular death) by 20% in people with obesity and established heart disease — the first anti-obesity medication to show that outcome.
Which one will insurance cover?
Insurance follows FDA approval. If you have type 2 diabetes, Ozempic is usually covered with a small copay after your deductible. If you don't have diabetes, plans typically require Wegovy — and many still exclude weight-loss drugs entirely. Check your plan's formulary and look for "GLP-1 receptor agonist" under diabetes or "anti-obesity medications" under weight management. Since 2024, some Medicare Part D plans cover Wegovy specifically for CV risk reduction in patients with heart disease.
If a claim is denied, ask your clinician to file a prior authorization documenting BMI, comorbidities, and prior weight-loss attempts. Denials are frequently overturned on appeal — especially when a BMI ≥30 or ≥27 with a documented comorbidity is on file.
Cost without insurance
List prices are ~$970 (Ozempic) and ~$1,350 (Wegovy) per month. Novo Nordisk's savings cards can drop copays for commercially insured patients but generally can't be used with Medicare or Medicaid. Compounded semaglutide from telehealth providers runs $150–$400/month, though the legal window narrowed sharply after the FDA declared the shortage resolved in 2024.
Side effects
Effectively identical: nausea, constipation, diarrhea, fatigue during dose escalation, and occasional burping. Wegovy's higher maximum dose can mean more intense GI symptoms in the ramp-up. Both carry the same boxed warning about medullary thyroid carcinoma (based on rodent studies), and both should be paused before elective surgery due to a small increased aspiration risk from delayed gastric emptying.
Can you switch between them?
Yes — many patients start on Ozempic (because insurance covers it under a diabetes diagnosis) and later request Wegovy for the higher weight-loss dose, or vice versa. Switching doesn't require restarting titration if you're moving to an equivalent or lower dose. Moving up from Ozempic 2 mg to Wegovy 2.4 mg is usually a single step-up.
Which should you ask for?
- Type 2 diabetes: Ozempic — it's the FDA-approved use and insurance is easier.
- Weight loss, insurance covers anti-obesity meds: Wegovy — higher dose, stronger effect.
- Weight loss, cash-pay: Compounded semaglutide through telehealth is usually the cheapest path.
- Heart disease + obesity, on Medicare: Wegovy may now qualify under the SELECT indication.
Questions worth asking your doctor
- Given my BMI and history, which one am I most likely to get covered?
- How slowly can we titrate the dose if I'm sensitive to nausea?
- What's the plan if I hit a weight-loss plateau at a mid-tier dose?
- How will we monitor kidney function, gallbladder symptoms, and thyroid history?
FAQ
Is Ozempic the same as Wegovy?
Both are semaglutide made by Novo Nordisk. Ozempic is FDA-approved for type 2 diabetes and dosed up to 2 mg/week; Wegovy is approved for chronic weight management and dosed up to 2.4 mg/week.
Which one causes more weight loss?
Wegovy, because the maximum dose is higher. Trials show ~15% body-weight loss on Wegovy 2.4 mg vs. ~6% on Ozempic 1 mg.
Can I use Ozempic for weight loss?
Clinicians sometimes prescribe it off-label, but insurance usually won't cover Ozempic unless you have type 2 diabetes.
How long until I see results?
Appetite usually drops within days. Meaningful weight loss shows by weeks 4–8, with most people hitting a plateau between months 9 and 15 at a maximum tolerated dose.
Do I need to inject at the same time each week?
Same day each week is ideal, but the exact time doesn't matter. If you miss a dose, take it within 5 days; otherwise skip it and resume your normal schedule.
Do the pens need refrigeration?
Unused pens go in the fridge. Once opened, they can stay at room temperature (below 86°F) for up to 56 days.
See which providers match your situation
Take a 90-second questionnaire and we'll rank your top 3 telehealth providers by medication, budget, and state availability.
Find My Top 3 MatchesEducational content, not medical advice. Talk to a licensed clinician before starting or changing any medication.